Core Viewpoint - Telix Pharmaceuticals Limited is facing a securities class action lawsuit following significant stock declines due to a regulatory subpoena and an FDA rejection letter [1] Group 1: Legal Proceedings - The lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., seeks to represent investors who acquired Telix securities between February 21, 2025, and August 28, 2025 [3] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][8] Group 2: Company Statements and Allegations - The litigation focuses on Telix's statements regarding its prostate cancer therapeutic candidates TLX591 and TLX592, as well as its kidney cancer detection candidate Zircaix [4] - During the class period, Telix claimed significant progress in its therapeutic pipeline and emphasized its global manufacturing capabilities as a competitive advantage [5] - The lawsuit alleges that Telix made false and misleading statements, overstating the progress of its prostate cancer candidates and the quality of its supply chain [5] Group 3: Regulatory Issues - On July 22, 2025, Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates, which negatively impacted its stock price [6] - On August 28, 2025, Telix received a Complete Response Letter from the FDA for its Zircaix BLA, citing deficiencies in chemistry, manufacturing, and controls, which further affected its stock performance [7]
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman